NCT06964776View on ClinicalTrials.gov

A Study of LY4268989 (MORF-057) in Healthy Participants

PHASE1RecruitingINTERVENTIONAL

Enrollment

114

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Healthy

Interventions

DRUG

LY4268989

Administered orally

DRUG

Placebo

Administered placebo

DRUG

Midazolam

Administered orally

DRUG

Midazolam

Administered intravenously (IV)

Trial Locations (1)

92801

RECRUITING

CenExel ACT, Anaheim

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY